
With the deadline for the FDA (US Food and Drug Administration)'s decision on Biogen's drug aducanumab fast approaching, analysts at RBC Capital Markets are less and less convinced that the result will be in Biogen's favor, writes Fiercepharma.
Aducanumab has faced many problems throughout the regulatory process. The application was turned down by an FDA expert committee in November, and the response deadline was pushed back by the agency in January.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app